A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions

Myasthenia Gravis

Interventions

DRUG

HBM9161 Injection (680mg and 340 mg)

HBM9161 Injection (680mg and 340mg)

DRUG

Placebos

Placebo, HBM9161 Injection (340mg)

DRUG

HBM9161 Injection (340 mg)

Trial Locations (1)

Huashan Hospital, Fudan University, Shanghai

All Listed Sponsors

lead

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY

NCT04346888 - A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients | Biotech Hunter | Biotech Hunter